{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-26-000008","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.337650+00:00","generated_at":"2026-05-15T22:14:23.552530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeuroPace Q4 rev $26.6M (+24%), FY25 rev $100M (+25%); guides FY26 $98-100M","bullets":["Q4 2025 revenue $26.6M (+24% YoY); RNS System revenue $22.4M (+26% YoY); gross margin 77.4%.","Full year 2025 revenue $100.0M (+25% YoY); net loss ($2.7M) Q4; Adj. EBITDA ($5.0M) FY25.","Submitted PMA-S to FDA for IGE indication expansion; NAUTILUS trial showed 77% median seizure reduction.","Reiterated FY26 guidance: total rev $98-100M (20-22% RNS growth); Adj. EBITDA ($9-10M).","DIXI Medical partnership ended Dec 31, 2025; discontinued ops reporting to begin Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-26-000008","json":"https://secwatch.observer/filing/0001528287-26-000008.json","markdown":"https://secwatch.observer/filing/0001528287-26-000008.md","text":"https://secwatch.observer/filing/0001528287-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828726000008/0001528287-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828726000008/npce-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:14:23.552530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}